News center

Jul 11, 2019

Catholic University of Korea Seoul St. Mary’s Hospital and Philips team up to improve cancer diagnosis


Catholic University of Korea Seoul St. Mary’s Hospital aims to increase diagnostic quality and turnaround times through digitization of pathology and use of artificial intelligence (AI)

Amsterdam, the Netherlands and Seoul, KoreaRoyal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced successful implementation of its Philips IntelliSite Pathology Solution at the Catholic University of Korea Seoul St. Mary’s Hospital. This digital pathology solution will help to achieve more efficient diagnosis, increased diagnostic accuracy, and ultimately support an improved quality of patient management in the pathology department.

 

“Freeing the pathology department from the conventional way of analyzing the tissue sample with a microscope, digital and computational pathology will enable us to bring a significant improvement to the efficiency and productivity of our workflow while conducting primary diagnosis with digital images,” said Professor Lee Youn-Soo, the Chief of the Pathology department at Seoul St. Mary’s Hospital. “Our primary objective of the introduction is delivering customized precision medicine service for the patients based on technologies and know-how Philips has long developed in the health care technology.”

Our primary objective of the introduction is delivering customized precision medicine service for the patients based on technologies and know-how Philips has long developed in the health care technology.

Professor Lee Youn-Soo

Chief of the Pathology department at Seoul St. Mary’s Hospital.

Pathology plays a critical role in disease detection, particularly in the diagnosis of cancer. Traditionally, suspicious tissue samples are examined under a microscope to determine if the tissue is malignant and consequently guide treatment decisions. The pathology department at Seoul St. Mary’s Hospital diagnoses over 50,000 histological cases each year, which translates to more than 250,000 slides of human tissue. Each of these slides needs to be prepared, analyzed, diagnosed, reported, and archived. Digitizing the tissue slide images eases collaboration across sites, reducing costs. It also facilitates access to specialists, allowing multi-disciplinary discussions to share expertise and knowledge, and ultimately come to a better diagnosis for the patient. 

 

In addition to providing a digital pathology solution, Philips will support Seoul St. Mary’s Hospital in several other ways so that the hospital can make the best use of it. This support includes real-time collaboration and consultation between pathologists, efficient multi-disciplinary team (MDT) meeting preparation and execution, networking hospitals under the Catholic University of Korea, and assisting the hospital to form a network with advanced hospitals around the world. In addition, Philips will support the hospital in building a large-scale database to store the data accumulated within the hospital’s digital and computational pathology organization and develop AI software algorithms, so that the hospital can offer patients customized diagnosis, treatment plans and prescriptions.

 

“We are honored to be able to work on a digital and computational pathology solution with Seoul St. Mary’s that delivers world-class health care based on advanced medical technology,” said Dong Hee Kim, Market Leader Philips Korea. “Philips is contributing to important changes that are leading the field of pathology in Korea by providing our digital and computational pathology technology and rich experience in health technology.” 

 

Philips IntelliSite Pathology Solution is an automated digital pathology solution for image creation, viewing and management. It comprises an ultra-fast scanner and image management system. It also contains advanced software tools to manage the scanning, storage, presentation, reviewing and sharing of images. The Philips IntelliSite Pathology solution can be used for in-vitro diagnostic purposes, helping pathologists to review and interpret digital images of surgical pathology slides prepared from formalin-fixed paraffin embedded (FFPE) tissue. It has market access clearance in over fifty countries. In 2018, Philips received MFDS approval to market Philips IntelliSite Pathology Solution for primary diagnostic use in South Korea.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2018 sales of EUR 18.1 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Read MoreRead Less

Topics

Contacts

Joost Maltha

Joost Maltha

Philips Group Press Office

Tel: +31 6 10 55 8116

Media assets

Philips IntelliSite Pathology Solution Ultra-Fast Scanner

Discover our latest images and more

Visit our new media library and find high-res images and more.

Share on social media